ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

11:30AM-1:00PM: Abstract Number: 0001

12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)

Plenary I

11:30AM-1:00PM: Abstract Number: 0002

Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy

Plenary I

11:30AM-1:00PM: Abstract Number: 0004

mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome

Plenary I

11:30AM-1:00PM: Abstract Number: 0003

Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial

Plenary I

11:30AM-1:00PM: Abstract Number: 0005

The Rheumatology Access Expansion (RAE) Initiative: Improving Rheumatoid Arthritis Care on Navajo Nation Through Primary Care Provider Education

Plenary I

1:00PM-3:00PM: Abstract Number: PP20

‘It Is Due to Stress’ – But Which Type of Stress? Cumulative childhood stress is a risk factor for autoimmune disease

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: 0213

“The Best Part Is Feeling Like I Could Go out There and Maybe Really Help Somebody”: Training Peer Coaches to Deliver the Moving Well Total Knee Replacement Telephone-Based Coaching Program

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0139

A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: PP09

A Matter of Life and Death: Why Diversity, Equity and Inclusion Matter for Health Care Providers

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: 0371

A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0479

A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Diagnosed GCA

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0311

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0194

A Survey of Patients with Ehlers Danlos Syndrome and Their Interest in Multidisciplinary Care

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0457

A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0487

A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1
2
3
…
39
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].